Last updated: February 23, 2026
What is the Drug NDC 51407-0090?
NDC 51407-0090 refers to Ubrogepant (brand name: Ubrelvy), a calcitonin gene-related peptide (CGRP) receptor antagonist approved by the FDA in 2019 for the acute treatment of migraines in adults. It is marketed by Allergan (AbbVie). The drug competes within the migraine-specific therapeutic market, especially against triptans and other CGRP antagonists.
Market Landscape
Market Size and Growth
The migraine treatment market reached approximately $4.2 billion in 2022, with a compound annual growth rate (CAGR) of 4% from 2018-2022. The introduction of CGRP antagonists like Ubrelvy expanded options for patients who do not tolerate traditional therapies.
Key Competitors
| Drug Name |
Class |
Market Share (2022) |
Notes |
| Ubrelvy (51407-0090) |
Oral CGRP receptor antagonist |
15% |
First-to-market oral CGRP for acute migraines |
| Ajovy |
CGRP monoclonal antibody |
20% |
Chronic and episodic prevention |
| Emgality |
CGRP monoclonal antibody |
17% |
Preventive use |
| Sumatriptan |
Triptan |
30% |
Established, generic options |
Patient Demographics
Approximately 39 million Americans suffer from migraines (CDC, 2019). About 40% of these patients experience episodic migraines, with a subset seeking acute treatment options.
reimbursement dynamics
Insurance coverage for CGRP antagonists remains favorable, but high out-of-pocket costs impact utilization. Manufacturers engage in aggressive discounts and patient assistance programs to penetrate the market.
Pricing Trends and Projections
Current Pricing
| Market Region |
Average Wholesale Price (AWP) |
Estimated Patient Out-of-Pocket Cost |
Notes |
| United States |
$55 per tablet |
$10-$20 (after insurance) |
Indication: acute migraine treatment |
| Europe |
€45 per tablet |
€5-€15 (with coverage) |
Variable by country |
Price Dynamics
- Launch Pricing (2019): Ubrelvy's retail price was approximately $50-$60 per tablet.
- Post-Pricing Adjustments: Manufacturers reduced prices by about 10-15% in 2022 to maintain competitive market share.
- Market Entry of Biosimilars: Not yet applicable (as it is a small-molecule drug).
Future Price Trends (2023-2027)
Predicted to decline marginally by 5-8% due to increased generic competition, price negotiations, and healthcare reforms.
| Year |
Estimated Price per Tablet |
Rationale |
| 2023 |
$50 |
Stable, slight discounts |
| 2024 |
$48 |
Entry of generics in some regions |
| 2025 |
$45 |
Increased generic and biosimilar options |
| 2026 |
$43 |
Cost pressure from healthcare systems |
| 2027 |
$41 |
Heightened competition and price sensitivity |
Regulatory and Patent Outlook
- Patent Expiry: Patents covering Ubrogepant extend until 2030 in the U.S., allowing some market exclusivity.
- Regulatory Approvals: Additional indications or formulations are under review, potentially impacting pricing strategies and market positioning.
Market Expansion Opportunities
- New Indications: Investigating preventive use or chronic migraine management may expand utilization.
- Geographic Expansion: Entry into emerging markets (e.g., Asia-Pacific) offers growth with lower initial price points.
- Combination Therapy: Potential for fixed-dose combinations to enhance adherence.
Key Market Indicators
- Insurance Coverage Trends: Favorable for CGRP antagonists but sensitive to drug pricing reforms.
- Reimbursement Policies: Shifting toward value-based care models may pressure pricing.
- Market Penetration: Ubrelvy's share is projected to grow modestly, driven by increased awareness and formulary inclusion.
Summary and Outlook
NDC 51407-0090 (Ubrelvy) is positioned in a growing migraine market with stable demand. Price projections indicate gradual declines mapping to increased competition and market saturation. Cost management strategies, such as formulary negotiations and patient assistance programs, will remain critical for market share maintenance.
Key Takeaways
- Ubrelvy's current price is around $50-$60 per tablet, with an expected decline to ~$41-$45 by 2027.
- The migraine treatment market is expanding, driven by increased adoption of CGRP antagonists.
- Patent expiration in 2030 offers potential for generics, influencing pricing strategies.
- Market growth depends on expanding indications, geographic regions, and reimbursement negotiations.
- Price sensitivity among healthcare systems and patients will influence future pricing dynamics.
FAQs
Q1: How does Ubrelvy compare in price to triptans?
A: Ubrelvy costs approximately $50-$60 per tablet, whereas generic triptans range from $2-$20 per dose, making triptans significantly cheaper but sometimes less tolerated.
Q2: What impact might biosimilars have on Ubrelvy's pricing?
A: Biosimilars are unlikely because Ubrelvy is a small molecule. However, generic CGRP antagonists could emerge, exerting downward pressure.
Q3: Are there any new formulations or indications under development?
A: No significant new formulations are currently approved, but ongoing trials explore preventive applications, which could broaden market size.
Q4: How does insurance coverage influence patient access?
A: While coverage is generally favorable, high out-of-pocket expenses can limit access, prompting manufacturers to offer assistance programs.
Q5: What regions represent growth opportunities?
A: Asia-Pacific, Latin America, and Eastern Europe offer emerging markets with growing migraine prevalence but require localized pricing strategies.
References:
[1] Centers for Disease Control and Prevention (CDC). (2019). Migraine prevalence.
[2] IQVIA. (2022). Pharmaceutical Market Data.
[3] FDA. (2019). Approval of Ubrelvy.
[4] GlobalData. (2022). Migraine therapeutics market analysis.
